In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Barrier Therapeutics grosses $46mm with Series B financing

Executive Summary

Newly formed Barrier Therapeutics (dermatology drug development; Johnson & Johnson spin-out) grossed $46mm with its Series B round private placement to JP Morgan Partners and TL Ventures, both of which served as lead investors, and to Perseus-Soros BioPharmaceutical Fund, Baker/Tisch Investment Partners, and KBC.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies